Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells $19,970.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $19.97, for a total value of $19,970.00. Following the transaction, the chief financial officer now owns 73,849 shares in the company, valued at approximately $1,474,764.53. This trade represents a 1.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, December 2nd, Kory James Wentworth sold 5,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00.
• On Monday, November 11th, Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock. The shares were sold at an average price of $19.98, for a total transaction of $172,567.26.
• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock opened at $20.32 on Friday. The firm has a market cap of $760.37 million, a PE ratio of 12.78 and a beta of -0.18. The business’s 50 day simple moving average is $17.98 and its 200 day simple moving average is $16.43. Entrada Therapeutics, Inc. has a 52-week low of $11.35 and a 52-week high of $20.50.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TRDA shares. Oppenheimer increased their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th. HC Wainwright upped their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

Institutional Trading of Entrada Therapeutics

A number of institutional investors have recently made changes to their positions in TRDA. Barclays PLC increased its stake in Entrada Therapeutics by 210.6% in the 3rd quarter. Barclays PLC now owns 45,110 shares of the company’s stock valued at $720,000 after buying an additional 30,585 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Entrada Therapeutics by 8.8% in the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after acquiring an additional 46,512 shares in the last quarter. Public Employees Retirement System of Ohio increased its position in shares of Entrada Therapeutics by 89.1% in the third quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock valued at $260,000 after acquiring an additional 7,659 shares during the last quarter. XTX Topco Ltd bought a new stake in Entrada Therapeutics during the third quarter worth about $634,000. Finally, State Street Corp boosted its position in Entrada Therapeutics by 5.5% during the third quarter. State Street Corp now owns 469,601 shares of the company’s stock valued at $7,504,000 after purchasing an additional 24,385 shares during the last quarter. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.